PA8596101A1 - Compuestos de triazol utiles en terapia - Google Patents
Compuestos de triazol utiles en terapiaInfo
- Publication number
- PA8596101A1 PA8596101A1 PA20048596101A PA8596101A PA8596101A1 PA 8596101 A1 PA8596101 A1 PA 8596101A1 PA 20048596101 A PA20048596101 A PA 20048596101A PA 8596101 A PA8596101 A PA 8596101A PA 8596101 A1 PA8596101 A1 PA 8596101A1
- Authority
- PA
- Panama
- Prior art keywords
- rent
- ring
- replaced
- optionally
- heterocicle
- Prior art date
Links
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical class C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 101150047265 COR2 gene Proteins 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
UN COMPUESTO DE LA FORMULA (I) O UN DERIVADO DEL MISMO FARMACEUTICAMENTE ACEPTABLE, EN DONDE V REPRESENTA -(CH2)D(O)E-, -CO-O-CH(ALQUILO C1-6)-; W ES -O-,-S(O)A-O-N(R1)- R1 REPRESENTA H, ALQUILO C 1-6, (CH2)BCOR2, CO(CH2)BNR2R3, SO2R2, (CH)COR2, (CH2)CNR2R3 O (CH2)BHET1; HET REPRESENTA UN HETEROCICLO SATURADO O INSATURADO DE 3 A 8 ATOMOS, CONTENIENDO UNO O MAS HETEROATOMOS SELECCIONADOS ENTRE O,N, O S, OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-6; X Y Y REPRESENTAN INDEPENDIENEMENTE H, ALQUILO C1-6, HALOGENO, OH, CF3, OCF3, OR4; Z REPRESENTA -(CH2)F(O)G-, -CO- O -CH(ALQUILO C1-6)-; EL ANILLO A REPRESENTA UN HETEROCICLO SATURADO DE 4-7 MIEMBROS CONTENIENDO N, OPCIONALMENTE AL MENOS UN N DEL ANILLO ES SUSTITUIDO CON O; EL ANILLO B REPRESENTA FENILO O UN HETEROCICLO INSATURADO DE 4-7 MIEMBROS CONTENIENDO N, OPCIONALMENTE SUSTITUIDO CON OH, Y EN EL CUAL OPCIONALMENTE AL MENOS UN N DEL ANILLO ES SUSTITUIDO CON O; EL ANILLO B REPRESENTA FENILO O UN HETEROCICLO INSATURADO DE 4-7 MIEMBROS CONTENIENDO N, OPCIONALMENTE SUSTITUIDO CON OH, HALOGENO, CN, CONH2, CF3, OCF3, Y EN EL QUE OPCIONALMENTE AL MENOS UN N DEL ANILLO ESTA SUSTITUIDO CON O; R2 y R3 INDEPENDIENTEMENTE REPRESENTA H, ALQUILO C1-6 [OPCIONALMENTE SUSTITUIDO CON OH, HALOGENO, N(ALQUILO C1-6)2, O ALQUILOXI C1-6], N(ALQUILO C1-6)2 O [CICLOALQUILO C3-8]; O R2 y R3, JUNTOS CON EL ATOMO DE NITROGENO AL CUAL ELLOS ESTAN INDEPENDIENTEMENTE UNIDOS, REPRESENTAN UN HETEROCICLO DE ENTRE 3 A 8 ATOMOS, OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-6; R4 REPRESENTA UN ALQUILO C1-6 RAMIFICADO O DE CADENA RECTA, A Y C REPRESENTAN INDEPENDIENTEMENTE 0,1 O 2; B,E Y G REPRESENTAN INDEPENDIENTEMENTE 0 O 1; D Y F REPRESENTAN INDEPENDIENTEMENTE 1 O 2; SON UTILES EN EL TRATAMIENTO DE DISMENORREA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0303852.8A GB0303852D0 (en) | 2003-02-19 | 2003-02-19 | Triazole compounds useful in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8596101A1 true PA8596101A1 (es) | 2005-08-04 |
Family
ID=9953327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20048596101A PA8596101A1 (es) | 2003-02-19 | 2004-02-18 | Compuestos de triazol utiles en terapia |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN1751047A (es) |
| AR (1) | AR043210A1 (es) |
| CL (1) | CL2004000293A1 (es) |
| GB (1) | GB0303852D0 (es) |
| GT (1) | GT200400020A (es) |
| NL (1) | NL1025527C2 (es) |
| PA (1) | PA8596101A1 (es) |
| PE (1) | PE20050222A1 (es) |
| TW (1) | TW200500367A (es) |
| UY (1) | UY28201A1 (es) |
| WO (1) | WO2004074291A1 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325021D0 (en) * | 2003-10-27 | 2003-12-03 | Pfizer Ltd | Therapeutic combinations |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| DE102004001871A1 (de) * | 2004-01-14 | 2005-09-01 | Bayer Healthcare Ag | Tricyclische Benzazepin-Derivate und ihre Verwendung |
| WO2006021882A1 (en) * | 2004-08-25 | 2006-03-02 | Pfizer Limited | Triazolobenzodiazepines and their use as vasopressin antagonists |
| CA2605899C (en) * | 2005-04-26 | 2011-02-08 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| EP2356123B1 (en) | 2008-11-13 | 2012-10-03 | F.Hoffmann-La Roche Ag | Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes |
| JP5384659B2 (ja) | 2008-11-18 | 2014-01-08 | エフ．ホフマン−ラ ロシュ アーゲー | ジヒドロテトラアザベンゾアズレンのアルキルシクロヘキシルエーテル |
| RU2507205C2 (ru) | 2008-11-28 | 2014-02-20 | Ф. Хоффманн-Ля Рош Аг | Арилциклогексилэфиры дигидротетраазабензоазуленов для применения в качестве антагонистов рецептора вазопрессина v1a |
| EP2414361A1 (en) | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Substituted heterocyclic compounds |
| CN102812011A (zh) * | 2009-11-16 | 2012-12-05 | 梅利科技公司 | [1,5]-二氮杂环辛间四烯衍生物 |
| US8420633B2 (en) * | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8492376B2 (en) * | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8481528B2 (en) * | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) * | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
| US9006450B2 (en) * | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| PE20140239A1 (es) | 2010-10-07 | 2014-03-07 | Takeda Pharmaceutical | Derivados de 1,4-oxazepano |
| RU2011122942A (ru) | 2011-06-08 | 2012-12-20 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Новые ингибиторы киназ |
| US8828989B2 (en) * | 2011-09-26 | 2014-09-09 | Hoffmann-La Roche Inc. | Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists |
| KR20140082765A (ko) * | 2011-10-05 | 2014-07-02 | 에프. 호프만-라 로슈 아게 | V1a 길항제로서의 사이클로헥실-4H,6H-5-옥사-2,3,10b-트라이아자-벤조[e]아줄렌 |
| PT2861566T (pt) | 2012-06-13 | 2017-02-08 | Hoffmann La Roche | Novos diazaspirocicloalcanos e azaspirocicloalcanos |
| CN102766674A (zh) * | 2012-07-25 | 2012-11-07 | 辉源生物科技（上海）有限公司 | 食蟹猴抗利尿激素受体v1a拮抗剂筛选平台的建立 |
| AU2013322838B2 (en) | 2012-09-25 | 2018-02-01 | F. Hoffmann-La Roche Ag | New bicyclic derivatives |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| EP3035939B1 (en) * | 2013-08-19 | 2020-03-25 | F. Hoffmann-La Roche AG | V1a antagonists to treat phase shift sleep disorders |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| WO2015082370A1 (en) | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| AU2015238537B2 (en) | 2014-03-26 | 2019-08-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| UA123362C2 (uk) | 2015-09-04 | 2021-03-24 | Ф. Хоффманн-Ля Рош Аг | Феноксиметильні похідні |
| CR20180057A (es) | 2015-09-24 | 2018-04-02 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. |
| KR20180053408A (ko) | 2015-09-24 | 2018-05-21 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물 |
| CR20180072A (es) | 2015-09-24 | 2018-02-26 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de atx |
| AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| SG11201908560SA (en) | 2017-03-16 | 2019-10-30 | Hoffmann La Roche | Heterocyclic compounds useful as dual atx/ca inhibitors |
| CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
| US11186577B2 (en) * | 2017-06-05 | 2021-11-30 | Blackthorn Therapeutics, Inc. | Vasopressin receptor antagonists and products and methods related thereto |
| HU231206B1 (hu) * | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| CN111170983B (zh) * | 2019-12-26 | 2021-07-09 | 中国农业大学 | 一种苄硫基乙酰胺类化合物及其制备方法与应用 |
| CN114644635B (zh) * | 2020-12-21 | 2023-02-03 | 上海济煜医药科技有限公司 | 三氮唑类三并环衍生物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823475D0 (en) * | 1988-10-06 | 1988-11-16 | Merck Sharp & Dohme | Chemical compounds |
| US5438035A (en) * | 1994-06-24 | 1995-08-01 | American Cyanamid Company | Methods for controlling undesirable plant species with benzodiazepine compounds |
| US5753648A (en) * | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| CA2268327C (en) * | 1996-11-01 | 2002-05-21 | American Home Products Corporation | 3-carboxamide derivatives of 5h-pyrrolo[2,1-c][1,4]-benzodiazepines |
| ES2207333T7 (es) * | 1999-01-19 | 2009-06-18 | Orto-Mcneil Pharmaceutical, Inc. | Benzodiazepinas triciclicas utilizadas como antagonistas del receptor de la vasopresina. |
| US7109193B2 (en) * | 2001-04-12 | 2006-09-19 | Wyeth | Tricyclic diazepines tocolytic oxytocin receptor antagonists |
-
2003
- 2003-02-19 GB GBGB0303852.8A patent/GB0303852D0/en not_active Ceased
-
2004
- 2004-02-09 CN CNA2004800047089A patent/CN1751047A/zh active Pending
- 2004-02-09 WO PCT/IB2004/000432 patent/WO2004074291A1/en not_active Ceased
- 2004-02-17 PE PE2004000165A patent/PE20050222A1/es not_active Application Discontinuation
- 2004-02-18 PA PA20048596101A patent/PA8596101A1/es unknown
- 2004-02-18 TW TW093103978A patent/TW200500367A/zh unknown
- 2004-02-18 AR ARP040100495A patent/AR043210A1/es not_active Application Discontinuation
- 2004-02-18 CL CL200400293A patent/CL2004000293A1/es unknown
- 2004-02-18 GT GT200400020A patent/GT200400020A/es unknown
- 2004-02-19 UY UY28201A patent/UY28201A1/es unknown
- 2004-02-19 NL NL1025527A patent/NL1025527C2/nl not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| UY28201A1 (es) | 2004-09-30 |
| CL2004000293A1 (es) | 2005-01-07 |
| CN1751047A (zh) | 2006-03-22 |
| NL1025527C2 (nl) | 2005-03-14 |
| NL1025527A1 (nl) | 2004-08-23 |
| TW200500367A (en) | 2005-01-01 |
| GT200400020A (es) | 2004-09-21 |
| AR043210A1 (es) | 2005-07-20 |
| WO2004074291A1 (en) | 2004-09-02 |
| GB0303852D0 (en) | 2003-03-26 |
| PE20050222A1 (es) | 2005-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8596101A1 (es) | Compuestos de triazol utiles en terapia | |
| CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| ECSP066647A (es) | Derivados de triazol como antagonistas de vasopresina | |
| DE60324155D1 (de) | Indol-3-carbinol metaboliten als chemotherapeutische und chemopräventive wirkstoffen | |
| ATE374777T1 (de) | Analoga als antitumorale verbindungen | |
| CO5580768A2 (es) | Derivados de 4,5-diariltiazol como ligandos cb-1 | |
| NO20062040L (no) | Modulatorer for atp-bindende kassett-transportere inneholdende cykloalkyl eller pyranylgrupper | |
| DE602004014347D1 (de) | Chinazolin-derivate als tgf-beta-inhibitoren | |
| AR039489A1 (es) | Derivados de tetrahidropiranil ciclopentil tetrahidropiridopiridina, moduladores de actividad de receptores de citoquinas | |
| PA8509301A1 (es) | Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias | |
| MY137944A (en) | Specific glucocorticoid compounds having anti-inflammatory activity | |
| GT200500098A (es) | Nuevos compuestos | |
| DE602006017715D1 (de) | Azol- und thiazolderivate und deren verwendung | |
| DE68927697D1 (de) | Fluor substituierte Benzocycloheptapyridine, Zusammensetzungen und Verfahren zur Verwendung derselben als antihistaminische Verbindungen | |
| CO5690599A2 (es) | Derivados de 3-(4-aminofenil) tienopirimid-4-ona como antagonistas mch r1 para el tratamiento de obesidad, diabetes, depresion y ansiedad | |
| DE602004023185D1 (de) | Phenylsulfonderivate und deren verwendung bei der behandlung von zns-erkrankungen | |
| NO20072060L (no) | 2-acylaminotiazolderivater | |
| CO6150166A2 (es) | Nuevos derivados de [1,3]tiazolo[4,5-d]pirimidin-2-(3h)-amina 5,7-disustituidos y su uso en terapia | |
| PA8563601A1 (es) | Acidos-3-(imidazolil)-2- alcoxipropanoicos | |
| ES2073258T3 (es) | Nuevos derivados de la urea, su preparacion y su aplicacion en terapeutica. | |
| ECSP055973A (es) | Compuestos de triazol utiles en terapia | |
| AR032358A1 (es) | Compuestos inhibidores del transporte de glicina, composicion farmaceutica y el uso de dichos compuestos para la fabricacion de un medicamento | |
| PA8550301A1 (es) | Proceso de produccion de quinazolina | |
| NO20051282L (no) | Antitumorale analoger av lamellariner. |